Hikma Pharmaceuticals to Invest $1B in US Manufacturing by 2030

• Hikma Pharmaceuticals has announced a $1 billion investment to expand its US manufacturing and R&D footprint by 2030.

Hikma Pharmaceuticals has unveiled a $1 billion investment plan to enhance its US-based manufacturing and research operations by 2030. The new investment phase, branded America Leans on Hikma: Quality Medicines Manufactured in the USA, will enhance Hikma’s established domestic capabilities to develop, manufacture, and supply a wide range of medicines required by the US healthcare system to treat patients across the country.

The announcement was made at a groundbreaking ceremony at the company’s facility in Columbus, Ohio. Elected officials including US Representatives Mike Carey and Buddy Carter attended the event in support of the initiative. The expansion covers Hikma’s R&D and manufacturing sites in Columbus and Cleveland, Ohio, and in Cherry Hill and Dayton, New Jersey.

This new phase builds on more than $4 billion in US investments over the past 15 years. Hikma currently has the capacity to produce over 12 billion finished doses annually and maintains a strong track record in FDA quality inspections. The company is also recognised for working with the FDA to address critical drug shortages.

“We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients,” said Dr Hafrun Fridriksdottir, President, Hikma Rx. “Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”

Dr Bill Larkins, President, Hikma Injectables, added: “Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients.”

The expansion is set to increase the volume of essential medicines developed and manufactured in the US, reinforcing Hikma’s position in the generic drug market and supporting the healthcare system with affordable treatments.